Key Developments: Mylan Inc (MYL.O)

MYL.O on Nasdaq

47.75USD
21 Aug 2014
Price Change (% chg)

$-0.84 (-1.73%)
Prev Close
$48.59
Open
$48.52
Day's High
$48.74
Day's Low
$47.66
Volume
3,786,623
Avg. Vol
4,464,185
52-wk High
$57.52
52-wk Low
$34.46

Search Stocks

Latest Key Developments (Source: Significant Developments)

Mylan Inc narrows FY 2014 revenue guidance; narrows FY 2014 EPS guidance to a range below analysts estimates; gives Q3 2014 EPS guidance below analysts estimates
Thursday, 7 Aug 2014 06:31am EDT 

Mylan Inc:Narrows FY 2014 guidance range for total revenue to $7.8 to $8.0 bln.Narrows FY 2014 adjusted diluted EPS to $3.25 to $3.45.Expects Q3 2014 adjusted diluted EPS in the range of $0.90 to $0.95.FY 2014 revenue of $7.8 bln and EPS of $3.37 - Thomson Reuters I/B/E/S.Q3 2014 EPS of $1.03 - Thomson Reuters I/B/E/S.  Full Article

Mylan Inc to acquire Abbott's non-U.S. developed markets specialty and branded generics business
Monday, 14 Jul 2014 06:30am EDT 

Mylan Inc:Has entered into a definitive agreement with Abbott Laboratories whereby Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business in an all-stock transaction.Upon closing, Abbott will receive 105 million shares of the combined company worth about $5.3 billion based on Mylan's closing price of $50.20 on July 11, representing an about 21 pct ownership stake.  Full Article

Mylan Inc reaffirms Q2 2014 EPS guidance
Tuesday, 1 Jul 2014 01:03pm EDT 

Mylan Inc:Expects Q2 2014 adjusted diluted earnings per share in the range of $0.67 to $0.70.Q2 2014 EPS of $0.67 - Thomson Reuters I/B/E/S.  Full Article

Mylan Inc launches generic Paraplatin Injection
Monday, 9 Jun 2014 07:30am EDT 

Mylan Inc:Has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin Injection.It is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents.  Full Article

Mylan Inc gives long term EPS guidance - Conference call
Wednesday, 14 May 2014 02:20pm EDT 

Mylan Inc:Says that it has laid out five-year roadmap that takes its EPS to $6, and doubling the size of company by FY 2018.FY 2014 EPS of $3.40, FY 2015 EPS of $3.90, FY 2016 EPS of $4.24, FY 2017 EPS of $4.35, FY 2018 EPS of $4.81 - Thomson Reuters I/B/E/S.  Full Article

Mylan Inc launches generic Zyprexa Zydis tablets
Wednesday, 14 May 2014 07:30am EDT 

Mylan Inc:Launched Olanzapine Orally Disintegrating Tablets (ODT), 5 mg, 10 mg, 15 mg and 20 mg, the generic version of Eli Lilly and Co's Zyprexa ZydisTablets.  Full Article

Mylan Inc reaffirms FY 2014 EPS outlook
Thursday, 1 May 2014 07:03am EDT 

Mylan Inc:Reaffirms FY 2014 adjusted diluted EPS guidance range of $3.25 to $3.60.FY 2014 EPS of $3.44 - Thomson Reuters I/B/E/S.  Full Article

Meda rejects revised proposal from Mylan Inc-DJ
Monday, 28 Apr 2014 03:57am EDT 

Meda AB:Rejects a revised offer for the company from Mylan Inc-DJ.Says all continued discussions between Meda and Mylan have been terminated without further actions.Prefers to remain a stand-alone company, while a lack of support from its largest shareholder would make it impossible to complete the transaction anyway.  Full Article

Actavis plc enters into an agreement with Mylan Inc. and Famy Care Ltd to settle patent litigation
Tuesday, 15 Apr 2014 08:00am EDT 

Actavis plc:Enters into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending Abbreviated New Drug Application (ANDA) beginning on April 1, 2015.Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on Oct. 1, 2015.Other terms of the settlement were not disclosed.  Full Article

Prosonix and Mylan Inc enter into global licensing agreement for generic versions of inhaled respiratory products flixotide and Flovent
Tuesday, 15 Apr 2014 08:00am EDT 

Prosonix:Says it has entered into a global licensing agreement with Mylan Inc, for its inhaled respiratory products, PSX1001 and PSX1050.Under the terms of the licensing agreement, Prosonix will file PSX1001 in the EU and retain marketing rights in certain territories.Mylan has marketing rights for PSX1001 and PSX1050 in the U.S., Canada, Australia, New Zealand, India, Japan, the EU, Iceland, Liechtenstein, Norway, Switzerland, Turkey, Russian Federation and the Commonwealth of Independent States.All other terms of the agreement remain confidential.  Full Article

U.S. judge blocks FDA rule allowing generic versions of Hospira drug

- A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.

Search Stocks